Scarica l'app Stockscreener
10.08
15.33%
1.34
Dopo l'orario di chiusura:
10.06
-0.02
-0.20%
Precedente Chiudi:
$8.74
Aprire:
$8.46
Volume 24 ore:
2.71M
Relative Volume:
2.20
Capitalizzazione di mercato:
$579.39M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-14.20
EPS:
-0.71
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
+6.78%
1M Prestazione:
+58.49%
6M Prestazione:
-38.34%
1 anno Prestazione:
-85.18%
Intervallo 1D:
$8.40
$10.53
Intervallo di 1 settimana:
$8.40
$10.53
Portata 52W:
$5.26
$74.00
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
10.08 | 579.39M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks (NYSE:DNA) Stock Price Up 4.1%Time to Buy? - MarketBeat
Teachers Retirement System of The State of Kentucky Cuts Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy - MSN
Ginkgo Bioworks joins project on cell-based disease treatment By Investing.com - Investing.com South Africa
Ginkgo Bioworks joins project on cell-based disease treatment - Investing.com
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program - PR Newswire
Charles Schwab Investment Management Inc. Decreases Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement - Law360
Janus Henderson Group PLC Has $118,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Trading Down 5.5%What's Next? - MarketBeat
Verition Fund Management LLC Takes Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Lowers Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
BNP Paribas Financial Markets Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Long Term Trading Analysis for (DNA) - Stock Traders Daily
279,954 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Ginkgo Bioworks CFO Mark Dmytruk sells $7,146 in stock By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells $3,182 in stock - Investing.com India
Ginkgo Bioworks CFO Mark Dmytruk sells $7,146 in stock - Investing.com
Ginkgo Bioworks executive sells $3,182 in stock By Investing.com - Investing.com UK
Synthetic Biology Market Forecast: $61.6 Billion by 2029, Growing at 26.1% CAGR - GlobeNewswire Inc.
Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover - Marketscreener.com
Erste Asset Management GmbH Purchases Shares of 500,000 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? - MSN
PDT Partners LLC Invests $1.20 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Anchorage Capital Group L.L.C. Trims Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
AH Capital Management L.L.C. Trims Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Advances Collaboration with Merck to Improve Bio - GuruFocus.com
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results - GuruFocus.com
Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Pre - GuruFocus.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Tao Capital Management LP - MarketBeat
US Bancorp DE Decreases Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates - MSN
How To Trade (DNA) - Stock Traders Daily
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Update - MarketBeat
GSA Capital Partners LLP Has $979,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St
Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ginkgo cancels move to new South Boston lab, exits Cambridge office - MassLive.com
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript - MSN
Ginkgo Bioworks: Not Enough Progress (NYSE:DNA) - Seeking Alpha
Baillie Gifford & Co. Sells 131,067,285 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Reports Q3 Growth and Strategic Deals - TipRanks
Ginkgo nixes move to South Boston lab, will exit Cambridge sites. Here's what it means - NBC Boston
Ginkgo nixes move to South Boston lab, will exit Cambridge sites - The Business Journals
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing - Marketscreener.com
Insights into Ginkgo Bioworks Holdings's Upcoming Earnings - Benzinga
Ginkgo Bioworks chief accounting officer sells $2,522 in stock - Investing.com India
Ginkgo Bioworks chief accounting officer sells $2,522 in stock By Investing.com - Investing.com Australia
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):